Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection

Transplantation

Volumn 94, Issue 2, 2012, Pages 114-122

  Bizargity, Peyman ^a   Liu, Kaifeng ^a   Wang, Liqing ^b   Hancock, Wayne W ^b   Visner, Gary A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute rejection; Dendritic cell; Lung transplantation; Mouse; Pirfenidone

Indexed keywords

CAS 53179 13 8; CD103 ANTIGEN; CD11B ANTIGEN; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PIRFENIDONE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELLULAR IMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE RESPONSE; DENDRITIC CELL; DOWN REGULATION; ENZYME PHOSPHORYLATION; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG INFILTRATE; LUNG INJURY; LUNG TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; CELL COMMUNICATION; CYTOKINES; DENDRITIC CELLS; GRAFT REJECTION; LUNG TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRIDONES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864281204     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182584879     Document Type: Article

References (35)

1. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040.
2. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143.
3. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; (9): CD003134.
4. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41: 1118.
5. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061.
6. Liu H, Drew P, Cheng Y, et al. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J Thorac Cardiovasc Surg 2005; 130: 852.
7. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginineYarginase pathway. Am J Transplant 2005; 5: 1256.
8. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant 2005; 24: 1577.
9. Visner GA, Liu F, Bizargity P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 2009; 88: 330.
10. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factorYbeta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367.
11. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003; 16: 207.
12. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419.
13. Liu G, Zhang L, Zhao Y. Modulation of immune responses through direct activation of Toll-like receptors to T cells. Clin Exp Immunol 2010; 160: 168.
14. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
15. del Rio ML, Bernhardt G, Rodriguez-Barbosa JI, et al. Development and functional specialization of CD103+ dendritic cells. Immunol Rev 2010; 234: 268.
16. del Rio ML, Rodriguez-Barbosa JI, Kremmer E, et al. CD103j and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J Immunol 2007; 178: 6861.
17. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85.
18. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352.
19. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335.
20. Xie J, Qian J, Wang S, et al. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol 2003; 171: 4792.
21. Lasky J. Pirfenidone. IDrugs 2004; 7: 166.
22. Dosanjh A, Ikonen T, Wan B, et al. Pirfenidone: a novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 2002; 15: 433.
23. Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol 2006; 35: 366.
24. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 2005; 11: 149.
25. Jakubzick C, Tacke F, Ginhoux F, et al. Blood monocyte subsets differentially give rise to CD103+ and CD103j pulmonary dendritic cell populations. J Immunol 2008; 180: 3019.
26. Feng Y, Wang D, Yuan R, et al. CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells. J Exp Med 2002; 196: 877.
27. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23: 203.
28. Kushner DJ, Baker A, Dunstall TG. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol 1999; 77: 79.
29. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081.
30. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71.
31. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703.
32. Arrighi JF, Rebsamen M, Rousset F, et al. A critical role for p38 mitogen-activated protein kinase in the maturation of human bloodderived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001; 166: 3837.
33. Yamamoto M, Sato S, Hemmi H, et al. TRAMis specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4: 1144.
34. Inaba K, Swiggard WJ, Steinman RM, et al. Isolation of dendritic cells. Curr Protoc Immunol 2009: chap 3.
35. Harding CV, Ramachandra L. Presenting exogenous antigen to T cells. Curr Protoc Immunol 2010; Chap 16.